BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Army
Express Scripts
Chubb
Federal Trade Commission
Fish and Richardson
US Department of Justice
Covington
Mallinckrodt
Citi
Dow

Generated: January 19, 2018

DrugPatentWatch Database Preview

FENOGLIDE Drug Profile

« Back to Dashboard

When do Fenoglide patents expire, and when can generic versions of Fenoglide launch?

Fenoglide is a drug marketed by Santarus Inc and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has twenty-nine patent family members in eleven countries.

The generic ingredient in FENOGLIDE is fenofibrate. There are forty-two drug master file entries for this compound. Fifty-five suppliers are listed for this compound. Additional details are available on the fenofibrate profile page.
Summary for FENOGLIDE
Drug patent expirations by year for FENOGLIDE
Medical Subject Heading (MeSH) Categories for FENOGLIDE

US Patents and Regulatory Information for FENOGLIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Santarus Inc FENOGLIDE fenofibrate TABLET;ORAL 022118-001 Aug 10, 2007 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Santarus Inc FENOGLIDE fenofibrate TABLET;ORAL 022118-002 Aug 10, 2007 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Santarus Inc FENOGLIDE fenofibrate TABLET;ORAL 022118-001 Aug 10, 2007 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Santarus Inc FENOGLIDE fenofibrate TABLET;ORAL 022118-002 Aug 10, 2007 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Santarus Inc FENOGLIDE fenofibrate TABLET;ORAL 022118-001 Aug 10, 2007 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Santarus Inc FENOGLIDE fenofibrate TABLET;ORAL 022118-001 Aug 10, 2007 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Santarus Inc FENOGLIDE fenofibrate TABLET;ORAL 022118-002 Aug 10, 2007 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Santarus Inc FENOGLIDE fenofibrate TABLET;ORAL 022118-002 Aug 10, 2007 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for FENOGLIDE
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Tablets 40 mg and 120 mg ➤ Subscribe 3/17/2010

Non-Orange Book US Patents for FENOGLIDE

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,772,273 Stabilized atorvastatin ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for FENOGLIDE

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chubb
Fuji
Moodys
Citi
Federal Trade Commission
McKinsey
Julphar
Covington
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot